In 2017, a group of internationally-recognized MRI industry professionals and entrepreneurs founded SpinTech, Inc. with the goal of transforming advanced MRI techniques, previously reserved only for the research realm, into practical applications to serve clinicians, pharmaceutical companies, and researchers alike. Our core technologies leverage three decades of leadership in the field of MRI and over $10M of R&D grants and investment.

Since our founding, our team has been instrumental in scientifically and clinically proving the importance of numerous imaging biomarkers for advancing the diagnosis and treatment of a wide range of neurological conditions. Collectively, our world-class team has published over 300 papers and received over 25,000 citations, supporting and validating our technology suite. As a company, we’ve grown rapidly with strategic partners and research hospitals from around the world.

In 2021, SpinTech acquired Magnetic Resonance Innovations, Inc. which began as a research and development and technology incubation company in 1994. Now as a combined entity, the company holds a robust patent portfolio with a continuous, rapid pace of innovation and development.

SpinTech continues to extend the boundaries of MRI and recently earned FDA clearance for STAGE, a rapid, quantitative multi-contrast imaging software that integrates seamlessly into existing clinical workflows. STAGE includes the world’s first FDA cleared QSM output and can be used across a wide range of neurodegenerative disorders such as stroke, Multiple Sclerosis, Parkinson’s, traumatic brain injury, dementia, and tumor imaging. In addition, SpinTech offers automated CMB and Parkinson’s Reports that run on top of STAGE data to aid clinicians in detecting microbleeds and quantifying neuromelanin content, respectively.